The toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Bollyky, Paul L ^a   Bice, Jeffrey B ^a   Sweet, Ian R ^c   Falk, Ben A ^b   Gebe, John A ^a   Clark, April E ^b   Gersuk, Vivian H ^a   Aderem, Alan ^b   Hawn, Thomas R ^c   Nepom, Gerald T ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; METRONIDAZOLE; MYELOID DIFFERENTIATION FACTOR 88; NEOMYCIN; STREPTOZOCIN; TOLL LIKE RECEPTOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL FLORA; C57BL 6 MOUSE; CELL DAMAGE; COMMENSAL; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HISTOPATHOLOGY; LIVER INJURY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN-SECRETING CELLS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; STREPTOZOCIN; TOLL-LIKE RECEPTORS;

EID: 64249140045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005063     Document Type: Article

References (59)

1. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21: 335-376.
2. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, et al. (1998) Targeted disruption of the Myd88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
3. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S (1999) Unresponsiveness of Myd88-deficient mice to endotoxin. Immunity 11: 115-122.
4. Jiang D, Liang J, Fan J, Yu S, Chen S, et al. (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173-1179.
5. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, et al. (2005) Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 41: 443-450.
6. Macedo L, Pinhal-Enfield G, Alshits V, Elson G, Cronstein BN, et al. (2007) Wound healing is impaired in Myd88-deficient mice: a role for Myd88 in the regulation of wound healing by adenosine A2A receptors. Am J Pathol 171: 1774-1788.
7. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
8. van Tol EA, Holt L, Li FL, Kong FM, Rippe R, et al. (1999) Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol 277: G245-G255.
9. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, et al. (2001) An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 166: 7128-7135.
10. Putnins EE, Sanaie AR, Wu Q, Firth JD (2002) Induction of keratinocyte growth factor 1 Expression by lipopolysaccharide is regulated by CD-14 and toll-like receptors 2 and 4. Infect Immun 70: 6541-6548.
11. Sanale AR, Firth JD, Uitto VJ, Putnins EE (2002) Keratinocyte growth factor (KGF)-1 and -2 protein and gene expression in human gingival fibroblasts. J Periodontal Res 37: 66-74.
12. Sugiyama A, Arakaki R, Ohnishi T, Arakaki N, Daikuhara Y, et al. (1996) Lipoteichoic acid and interleukin 1 stimulate synergistically production of hepatocyte growth factor (scatter factor) in human gingival fibroblasts in culture. Infect Immun 64: 1426-1431.
13. Uematsu S, Matsumoto M, Takeda K, Akira S (2002) Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/Myd88/NF-IL6 pathway. J Immunol 168: 5811-5816.
14. Thomas KE, Sapone A, Fasano A, Vogel SN (2006) Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are Myd88-dependent: role of the innate immune response in Celiac disease. J Immunol 176: 2512-2521.
15. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, et al. (2004) Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53: 987-992.
16. Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118: 671-674.
17. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, et al. (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 47: 571-579.
18. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022-1023.
19. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
20. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, et al. (2008) Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 22: 2416-2426.
21. Vives-Pi M, Somoza N, Fernandez-Alvarez J, Vargas F, Caro P, et al. (2003) Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 133: 208-218.
22. Wen L, Peng J, Li Z, Wong FS (2004) The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 172: 3173-3180.
23. Takahashi K, Satoh J, Seino H, Zhu XP, Sagara M, et al. (1993) Prevention of type I diabetes with lymphotoxin in BB rats. Clin Immunol Immunopathol 69: 318-323.
24. Sai P, Rivereau AS (1996) Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab 22: 341-348.
25. Balasa B, van Gunst K, Sarvetnick N (2000) The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: implications for the etiology of autoimmune diabetes. Clin Immunol 95: 93-98.
26. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, et al. (2006) Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 55: 179-185.
27. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, et al. (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49: 2105-2108.
28. van der WN, Kroese FG, Rozing J, Hillebrands JL (2007) Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 23: 169-183.
29. Sobel DO, Ewel CH, Zeligs B, Abbassi V, Rossio J, et al. (1994) Poly I:C induction of alpha-interferon in the diabetes-prone BB and normal Wistar rats. Dose-response relationships. Diabetes 43: 518-522.
30. Serreze DV, Hamaguchi K, Leiter EH (1989) Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 2: 759-776.
31. Uematsu S, Jang MH, Chevrier N, Guo Z, Kumagai Y, et al. (2006) Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7: 868-874.
32. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, et al. (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455: 1109-1113.
33. Weibel ER, Staubli W, Gnagi HR, Hess FA (1969) Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver. J Cell Biol 42: 68-91.
34. Montana E, Bonner-Weir S, Weir GC (1993) Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest 91: 780-787.
35. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, et al. (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47: 358-364.
36. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
37. Collins TJ (2007) ImageJ for microscopy. Biotechniques 43: 25-30.
38. Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, et al. (1990) Islet isolation assessment in man and large animals. Acta Diabetol Lat 27: 185-195.
39. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238.
40. Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, et al. (2002) Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 298: 1424-1427.
41. O'Brien BA, Harmon BV, Cameron DP, Allan DJ (1996) Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 176-181.
42. Saini KS, Thompson C, Winterford CM, Walker NI, Cameron DP (1996) Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic beta cell line, INS-1. Biochem Mol Biol Int 39: 1229-1236.
43. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, et al. (2006) Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci U S A 103: 13468-13473.
44. Drucker DJ (2003) Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144: 5145-5148.
45. Heald KA, Jay TR, Topham D, Webberley J, Downing R (1996) The effect of gnotobiotic rearing on porcine islet isolation and function. Transplant Proc 28: 824-825.
46. Gelman AE, Zhang J, Choi Y, Turka LA (2004) Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172: 6065-6073.
47. Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, et al. (2005) Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 174: 3633-3642.
48. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
49. Lombardo E, Alvarez-Barrientos A, Maroto B, Bosca L, Knaus UG (2007) TLR4-mediated survival of macrophages is Myd88 dependent and requires TNF-alpha autocrine signalling. J Immunol 178: 3731-3739.
50. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A (2000) The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 19: 3325-3336.
51. Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, et al. (2007) Role of toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg Today 37: 867-873.
52. Salaun B, Romero P, Lebecque S (2007) Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 37: 3311-3318.
53. Cornell RP (1985) Endogenous gut-derived bacterial endotoxin tonically primes pancreatic secretion of insulin in normal rats. Diabetes 34: 1253-1259.
54. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, et al. (1998) IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 102: 516-526.
55. Saitoh N, Awaya A, Sakudo A, SungWook S, Saeki K, et al. (2004) Serum thymic factor prevents LPS-induced pancreatic cell damage in mice via upregulation of Bcl-2 expression in pancreas. Microbiol Immunol 48: 629-638.
56. Oguri S, Motegi K, Iwakura Y, Endo Y (2002) Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysaccharide-induced hypoglycemia in mice. Clin Diagn Lab Immunol 9: 1307-1312.
57. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, et al. (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292: E740-E747.
58. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, et al. (2005) Five-year follow-up after clinical islet transplantation. Diabetes 54: 2060-2069.
59. Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ (1977) Endotoxin and bacteria in portal blood. Gastroenterology 72: 1268-1270.